The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release HNO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.

The present invention is related to the inhibition of the formation of Streptococci biofilms through the inhibition of glucosyl transferase (Gtf). Compounds, compositions and methods for inhibiting Streptococcus biofilm formation, as well as for preventing, inhibiting and/or treating the formation of dental caries, and methods of identifying compounds that prevent, inhibit and/or treat the formation of dental caries are provided.

The present invention is related to the inhibition of the formation of Streptococci biofilms through the inhibition of glucosyl transferase (Gtf). Compounds, compositions and methods for inhibiting Streptococcus biofilm formation, as well as for preventing, inhibiting and/or treating the formation of dental caries, and methods of identifying compounds that prevent, inhibit and/or treat the formation of dental caries are provided.

Compounds of general formula (Ia), compounds of general formula (Ia), compounds of general formula (Ib), compounds of general formula (Ib), compounds of general formula (I), compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.8, R.sup.9, X.sup.1, X.sup.2, and X.sup.3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds of the disclosure.

Compounds of general formula (Ia), compounds of general formula (Ia), compounds of general formula (Ib), compounds of general formula (Ib), compounds of general formula (I), compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.8, R.sup.9, X.sup.1, X.sup.2, and X.sup.3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds of the disclosure.

Compounds of general formula (Ia), compounds of general formula (Ia), compounds of general formula (Ib), compounds of general formula (Ib), compounds of general formula (I), compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.8, R.sup.9, X.sup.1, X.sup.2, and X.sup.3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds of the disclosure.

Compounds of general formula (Ia), compounds of general formula (Ia), compounds of general formula (Ib), compounds of general formula (Ib), compounds of general formula (I), compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.8, R.sup.9, X.sup.1, X.sup.2, and X.sup.3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds of the disclosure.

The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release HNO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.

The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release HNO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.

A liquid crystal compound is represented by formula (1): ##STR00001## In formula (1), R.sup.1 is alkyl or the like; ring A.sup.1 and ring A.sup.2 are independently 1,4-cyclohexylene, 1,4-phenylene or the like; Z.sup.1, Z.sup.2 and Z.sup.3 are independently a single bond, CF.sub.2O or the like; X.sup.1 is fluorine, chlorine, CF.sub.3 or the like; L.sup.1 and L.sup.2 are independently hydrogen, fluorine or the like; a and b are independently 0, 1, 2 or 3; and W is a group represented by formula (1a) or formula (1b); ##STR00002## In formula (1a) and formula (1b), L.sup.3 to L.sup.8 are independently hydrogen, fluorine or the like.